Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 8

Unmet Needs in Third-Line mCRC: Challenges and Opportunities

December 12, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss the most significant unmet needs in treating third-line metastatic colorectal cancer (mCRC), highlight areas where additional research is needed to improve patient outcomes, and explore investigational agents they find promising for future treatment options.

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

Now Viewing

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

What are the most significant unmet needs currently in treating mCRC in the third-line setting?
What additional research is needed to improve patient outcomes? Are there any investigational agents that you are excited about? (potential list below, feel free to comment on any others)